Does Administration of Antibiotics in Patients Undergoing Surgery for Colorectal Cancer Result in Less Complications and Better Prognosis?

Colorectal Cancer Clinical Trial

— SELECT  

Official title:

Perioperative Selective Decontamination of the Digestive Tract (SDD) in Elective Colorectal Cancer Patients: a Multicenter Randomized Clinical Trial

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01740947
• Other study ID #: 2011-002211-28
• Status: Terminated
• Phase: Phase 4
• Start date: January 2013
• Est. completion date: March 2017

Study information

• Verified date: November 2018
• Source: VU University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objectives of this randomized clinical trial are to evaluate if perioperative SDD can reduce clinical anastomotic leakage rate and its septic consequences as well as other infectious complications. By reduction of septic complications long-term oncological outcome might simultaneously improve.

Description:

Rationale:

Infectious complications and especially anastomotic leakage severely impede the recuperation of patients following colorectal cancer surgery. When the normal gut barrier fails such as in anastomotic leakage, pathogenic microorganisms like Gram-negative bacteria enter the circulation and may cause severe sepsis which is associated with considerable mortality. Moreover, anastomotic leakage has a negative impact on colorectal cancer prognosis. Selective decontamination of the digestive tract (SDD) is a prophylaxis regimen that employs oral nonabsorbable antibiotics to eradicate pathogenic micro-organisms like Gram-negative bacteria.

Objective:

The primary objectives of this randomized clinical trial are to evaluate if perioperative SDD can reduce clinical anastomotic leakage rate and its septic consequences as well as other infectious complications. By reduction of septic complications long-term oncological outcome might simultaneously improve. Secondary objectives are a decline in reoperation rate, in-hospital mortality, readmission rate, duration of hospital stay and ICU admission, non-infectious complications, improvement of quality of life and reduction of costs.

Study design:

A randomised multicenter clinical trial comparing perioperative SDD in addition to standard antibiotic prophylaxis with standard antibiotic prophylaxis alone in patients with colorectal cancer who undergo elective surgical resection with curative intent.

Study population:

Patients 18 years or older are eligible for inclusion when they are diagnosed with colon or rectal cancer without signs of distant metastases. Patients may be scheduled for either laparoscopic or open resection with curative intent, including construction of an anastomosis (either with or without diverting stoma). Patients are not eligible for inclusion in case of concomitant metastases or acute obstruction.

Intervention:

Patients are randomly allocated for either perioperative SDD (intervention group) including standard antibiotic prophylaxis or standard treatment (including standard antibiotic prophylaxis alone) (control group). The solution containing SDD is orally taken 4 times daily, starting 3 days before surgery and continued until normal bowel passage or at least 3 days after surgery. Both groups receive a single preoperative intravenous dose of 1000 mg Cefazoline and 500 mg Metronidazole, which is the current standard antibiotic prophylaxis.

Main study parameters/endpoints:

The main study parameter is anastomotic leakage. The research hypothesis refers to an estimated decrease in anastomotic leakage rate in the SDD treated group (from 9% to 4%). As anastomotic leakage has been shown unfavourable forlong term oncological outcome, we presume an improvement in disease free survival, which serves as important secondary endpoint.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 485
• Est. completion date: March 2017
• Est. primary completion date: March 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Elective colon and rectal cancer surgery with primary anastomosis

• Or elective colorectal surgery for suspected carcinoma

• No evidence of distant metastases (preoperative CT-abdomen and X-thorax or CTthorax)

• Procedure either with or without diverting stoma

• Both laparoscopic and open surgery

• Informed consent

• Aged 18 years or older

Exclusion Criteria:

• Previous colorectal malignancy

• Current malignancy which is now undergoing treatment

• Inflammatory bowel disease (Crohn's disease or ulcerative colitis)

• Previous surgery for diverticular disease

• Performance status ASA 4 or higher (American Society for Anaesthesiologists)

• Expected adverse reactions/allergies for study medication

• Prednisone use > 5 mg per day

• Familial adenomatous polyposis coli (FAP; Lynch syndrome), Hereditary Non Polyposis Colorectal Cancer (HNPCC)

• Mental disorder/unable to give informed consent

• Pregnancy

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms

Intervention

Drug:
• Selective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B)
SDD suspension contains per dose of 10 ml 100 mg colistin sulfate, 80 mg tobramycin and 500 mg amphotericin B

Locations

Country	Name	City	State
Netherlands	Slotervaart Ziekenhuis	Amsterdam
Netherlands	VU University Medical Center	Amsterdam
Netherlands	Kennemer Gasthuis	Haarlem
Netherlands	Spaarne Ziekenhuis	Hoofddorp
Netherlands	WestFries Gasthuis	Hoorn

Sponsors (2)

Lead Sponsor	Collaborator
H. Jaap Bonjer, PhD	Dutch Digestive Diseases Foundation

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Other postoperative infectious complications	pneumonia, urinary tract infections, surgical site infections, wound dehiscence, (remote) intraabdominal abscess	30 days postoperatively
Other	Non-infectious complications	cardiac failure, cerebrovascular events, deep venous thrombosis	30 days postoperatively
Other	In-hospital mortality		30 days postoperatively
Other	Readmission rate		5 years postoperatively
Other	Reoperation rate		5 years postoperatively
Other	Duration of hospital stay		30 days postoperatively
Other	Quality of life (quality adjusted life years)		2 years postoperatively
Other	In hospital and out-of-hospital costs		5 years postoperatively
Primary	anastomotic leakage and/or abscess	clinical and/or radiological evidence of anastomotic dehiscence requiring surgical or radiological (re)intervention.	30 days postoperatively
Secondary	Disease free survival		3 and 5 years after inclusion